典型文献
Current status and perspectives of regulatory T cell-based therapy
文献摘要：
The CD4+FOXP3+regulatory T(Treg)cells are essential for maintaining immune homeostasis in healthy individuals.Results from clinical trials of Treg cell-based therapies in patients with graft versus host disease(GVHD),type 1 diabetes(T1D),liver transplantation,and kidney transplantation have demonstrated that adoptive transfer of Treg cells is emerging as a promising strategy to promote immune tolerance.Here we provide an overview of recent progresses and current challenges of Treg cell-based therapies.We sum-marize the completed and ongoing clinical trials with human Treg cells.Notably,a few of the chimeric antigen receptor(CAR)-Treg cell therapies are currently undergoing clinical trials.Meanwhile,we describe the new strategies for engineering Treg cells used in preclinical studies.Finally,we envision that the use of novel synthetic receptors,metabolic regulators,combined therapies,and in vivo generated antigen-specific or engineered Treg cells through the delivery of modified mRNA and CRISPR-based gene editing will further promote the advances of next-generation Treg cell therapies.
文献关键词：
中图分类号：
作者姓名：
Guojun Qu;Jieqiong Chen;Yangyang Li;Yaqin Yuan;Rui Liang;Bin Li
作者机构：
Shanghai Institute of Immunology,Department of Immunology and Microbiology,Shanghai Jiao Tong University School of Medicine,Shanghai Jiao Tong University,Shanghai 200025,China;Shanghai Affinity Biopharmaceutical Co.,Ltd.,781 Cailun Road,Shanghai 201203,China;Unit of Immune and Metabolic Regulation,School of Life Science and Technology,ShanghaiTech University,Shanghai 201210,China
文献出处：
引用格式：
[1]Guojun Qu;Jieqiong Chen;Yangyang Li;Yaqin Yuan;Rui Liang;Bin Li-.Current status and perspectives of regulatory T cell-based therapy)[J].遗传学报,2022(07):599-611
A类：
CD4+FOXP3+regulatory
B类：
Current,status,perspectives,therapy,Treg,cells,are,essential,maintaining,immune,homeostasis,healthy,individuals,Results,from,trials,therapies,patients,graft,versus,host,disease,GVHD,type,diabetes,T1D,transplantation,kidney,have,demonstrated,that,adoptive,transfer,emerging,promising,strategy,promote,tolerance,Here,we,provide,overview,recent,progresses,challenges,We,sum,marize,completed,ongoing,human,Notably,few,chimeric,antigen,CAR,currently,undergoing,Meanwhile,describe,new,strategies,engineering,used,preclinical,studies,Finally,envision,novel,synthetic,receptors,metabolic,regulators,combined,vivo,generated,specific,engineered,through,delivery,modified,CRISPR,editing,will,further,advances,next,generation
AB值：
0.613498
相似文献
机标中图分类号，由域田数据科技根据网络公开资料自动分析生成，仅供学习研究参考。
